Literature DB >> 10355770

A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey.

K Shinohara, K Sakai, S Ando, Y Ami, N Yoshino, E Takahashi, K Someya, Y Suzaki, T Nakasone, Y Sasaki, M Kaizu, Y Lu, M Honda.   

Abstract

A highly pathogenic simian/human immunodeficiency virus (SHIV), designated C2/1, was obtained by serum passages in cynomolgus monkeys of p-SHIV, an SHIV strain that contains the env gene of pathogenic human immunodeficiency virus type 1 89.6. CD4+ lymphocyte depletion was induced within 1 week of the SHIV-C2/1 infection in peripheral blood as well as in various lymphoid organs in all the animals tested, with symptoms of diarrhoea and no increase in body weight, followed by intense viraemia. Serum antibody against Env protein was detected from 4 weeks after the virus infection, while the anti-Gag antibody response was absent in the SHIV-C2/1-infected animals. In contrast, both anti-Gag and anti-Env antibody responses were present in animals infected with p-SHIV or the non-pathogenic SHIV-MN. Sequencing of the env gene of isolates of SHIV-C strains showed conserved amino acid changes in the Env C2 and V3 regions that included changes to negatively charged amino acids, in the cytoplasmic region of gp41 that included a 42 amino acid deletion, and in the Nef protein. The pathogenic SHIV-C2/1-monkey model suggests that virus-specific pathogenicity in SHIV infection may be associated with the absence of anti-Gag antibody responses in animals and may be caused by genetic changes during serum passage in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10355770     DOI: 10.1099/0022-1317-80-5-1231

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  Induction of CD95 ligand expression on T lymphocytes and B lymphocytes and its contribution to apoptosis of CD95-up-regulated CD4+ T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus.

Authors:  Y Sasaki; Y Ami; T Nakasone; K Shinohara; E Takahashi; S Ando; K Someya; Y Suzaki; M Honda
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

2.  Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study.

Authors:  Tadashi Nakasone; Sei Kumakura; Michiko Yamamoto; Tsutomu Murakami; Naoki Yamamoto
Journal:  Med Microbiol Immunol       Date:  2012-07-08       Impact factor: 3.402

3.  Small intestine CD4+ T cells are profoundly depleted during acute simian-human immunodeficiency virus infection, regardless of viral pathogenicity.

Authors:  Yoshinori Fukazawa; Ariko Miyake; Kentaro Ibuki; Katsuhisa Inaba; Naoki Saito; Makiko Motohara; Reii Horiuchi; Ai Himeno; Kenta Matsuda; Megumi Matsuyama; Hidemi Takahashi; Masanori Hayami; Tatsuhiko Igarashi; Tomoyuki Miura
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

4.  Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Authors:  Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Authors:  Kenji Someya; Dayaraj Cecilia; Yasushi Ami; Tadashi Nakasone; Kazuhiro Matsuo; Sherri Burda; Hiroshi Yamamoto; Naoto Yoshino; Masahiko Kaizu; Shuji Ando; Kenji Okuda; Susan Zolla-Pazner; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 6.  Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences.

Authors:  Gregory Q Del Prete; Jeffrey D Lifson; Brandon F Keele
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

7.  Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.

Authors:  Yasuyuki Eda; Mari Takizawa; Toshio Murakami; Hiroaki Maeda; Kazuhiko Kimachi; Hiroshi Yonemura; Satoshi Koyanagi; Kouichi Shiosaki; Hirofumi Higuchi; Keiichi Makizumi; Toshihiro Nakashima; Kiyoshi Osatomi; Sachio Tokiyoshi; Shuzo Matsushita; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Small intestine CD4+ cell reduction and enteropathy in simian/human immunodeficiency virus KS661-infected rhesus macaques in the presence of low viral load.

Authors:  Katsuhisa Inaba; Yoshinori Fukazawa; Kenta Matsuda; Ai Himeno; Megumi Matsuyama; Kentaro Ibuki; Yoshiharu Miura; Yoshio Koyanagi; Atsushi Nakajima; Richard S Blumberg; Hidemi Takahashi; Masanori Hayami; Tatsuhiko Igarashi; Tomoyuki Miura
Journal:  J Gen Virol       Date:  2009-11-04       Impact factor: 3.891

10.  Early bone marrow hematopoietic defect in simian/human immunodeficiency virus C2/1-infected macaques and relevance to advance of disease.

Authors:  Kenji Yamakami; Mitsuo Honda; Masami Takei; Yasushi Ami; Noboru Kitamura; Susumu Nishinarita; Shigemasa Sawada; Takashi Horie
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.